Oscar Health, Inc. (OSCR) — Fundamental Analysis

Oscar Health has pulled off one of the more dramatic financial turnarounds in the health insurance space. After years of deep losses — burning through hundreds of millions annually while scaling its tech-driven individual health insurance business — the company crossed into meaningful profitability for the first time in 2024 and has continued to accelerate in the most recent quarter ended June 2026. Revenue has exploded from under $500 million five years ago to nearly $12 billion in fiscal 2025, a pace of growth that few insurers of any size have matched. The path wasn't smooth: operating margins were still modestly negative in 2025 on an annual basis, and liquidity ratios hover close to 1x, meaning the balance sheet warrants watching. But the most current quarterly data tells a more encouraging story — Oscar is now generating real operating income and its debt load relative to equity remains modest. For long-term investors, the core question has shifted from "will Oscar survive?" to "how durable is the profitability now emerging at scale?"

Snapshot & Big Picture

Oscar Health operates as a technology-focused health insurance carrier, primarily selling individual and small-group plans through the Affordable Care Act marketplaces. Its growth thesis has always rested on using data and software to manage medical costs better than legacy insurers. For most of its public life, that thesis was expensive to prove — the company posted losses every single year from 2019 through 2023, with operating margins as bad as -87% in 2020 when it was still small. The story changed in 2024, when Oscar posted its first profitable year at the operating line, and the most recent quarterly filing suggests that improvement is deepening.

Note that 2025 saw margins dip back into negative territory after 2024's breakeven — a reminder that ACA marketplace insurers face year-to-year variability in medical loss ratios, and scale alone does not guarantee consistent profitability. Gross margin figures were not available in any of the annual filings reviewed.

Latest Quarter Snapshot

The most recent data — covering the quarter ended June 30, 2026, as reported in Oscar's 10-Q filed August 7, 2026 — is considerably more current than the 2025 annual figures and paints a meaningfully brighter picture. This is the most up-to-date window into Oscar's financial condition.

Operating and net margins near 8% in a single quarter represent a substantial leap from where Oscar stood even a year prior. The current ratio has climbed above 1.0x and debt-to-equity has fallen to 0.21x, both pointing toward improved near-term financial stability compared to the 2025 annual snapshot.

Profitability

The multi-year profitability trend is one of steady, if uneven, improvement. Oscar's operating margin went from -87% in 2020 to roughly breakeven in 2024 — a remarkable compression of losses as the business scaled. The slight regression in 2025 (-3.4% operating margin) reflects the reality of health insurance underwriting: medical costs can spike in any given policy year, temporarily pressuring margins even as the structural cost management improves. The Q2 2026 quarterly reading of +8% operating margin, if it holds through the year, would represent a decisive step into sustained profitability. EBITDA turned positive for the first time in 2024 at $89 million, then swung negative again in 2025 at -$367 million, before rebounding sharply in the most recent quarter. Gross margin data was not available in the filings for any period covered.

Financial Health

Oscar's balance sheet has strengthened as it has grown, though it is not without blemish. The current ratio — a basic measure of whether short-term assets cover short-term liabilities — dipped to 0.82x at year-end 2024 and 0.95x at year-end 2025, both below the comfortable 1.0x threshold. As of the most recent quarter (June 2026), it has recovered to 1.08x, which is a positive development. Debt-to-equity has remained conservative throughout, ranging from 0.30x to 0.44x in recent annual periods and falling to 0.21x in the latest quarter, suggesting Oscar has not relied heavily on leverage to fund its growth.

Capital Expenditures: Oscar is a notably light capital spender — fitting for a company whose product is insurance rather than physical infrastructure. CapEx has ranged from $14 million to $36 million annually and has trended modestly upward in absolute dollar terms as the business has grown, while falling sharply as a percentage of revenue. In 2019, CapEx consumed 5.3% of revenue; by 2025 that ratio had fallen to 0.31%, and the most recent quarter came in at just 0.18% of revenue. This declining capital intensity is a meaningful quality signal — it means Oscar can grow its top line without proportionally reinvesting in hard assets, which is consistent with a software-enabled insurance model and supports long-run free cash flow generation once underwriting becomes consistently profitable.

Growth

Oscar's revenue growth has been extraordinary by almost any standard. The company grew from a small regional insurer into a nearly $12 billion revenue business in roughly half a decade, driven by ACA marketplace expansion, member growth, and premium increases.

A 3-year revenue CAGR of 43.5% and a 5-year CAGR of 90.8% are exceptional figures, though some of the 5-year rate reflects the unusual base — 2020 was a year in which revenue actually declined slightly and remained small relative to what followed. Either way, the trajectory confirms that Oscar has successfully scaled its membership base at a rapid pace; the central challenge going forward is translating that scale into durable, consistent profitability rather than episodic breakeven performance.

Source Filings

• 10-Q filed August 7, 2026 — period ended June 30, 2026
• 10-Q filed May 7, 2026 — period ended March 31, 2026